person · Reporting owner
Schneider Joel Solomon Zev
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Operating Officer | March 14, 2022 | March 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date March 14, 2022 · Filed March 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,542 |
Reported balance
After 2022-03-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-14 · Sale · Disposed 15,232 · Balance 251,542 F1: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). F2: Reflects a correction as to the number of securities previously reported in Column 5 of Table I due to an arithmetical error. |
| Common StockSEC Table I · non-derivative | Direct | 236,270 |
Reported balance
After 2022-03-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-03-14 · Sale · Disposed 15,272 · Balance 236,270 F1: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
F2: Reflects a correction as to the number of securities previously reported in Column 5 of Table I due to an arithmetical error.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2022 Filed Mar 15, 2022 21:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 15,272 | $1.10 | $16,799.20 |
DisclosureSEC source: 0001209191-22-018883 · doc4.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,270 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 21:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 15,232 | $1.10 | $16,755.20 |
DisclosureSEC source: 0001209191-22-018883 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,542 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). F2 · balance_after: Reflects a correction as to the number of securities previously reported in Column 5 of Table I due to an arithmetical error. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:35 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005695 · doc4.xml · derivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:35 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-22-005695 · doc4.xml · derivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,699 | $8.84 | $103,451.92 |
DisclosureSEC source: 0001209191-21-020432 · doc4.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,774 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 12, 2020. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,699 | $8.84 | $103,468.30 |
DisclosureSEC source: 0001209191-21-020432 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,473 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 12, 2020. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:21 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001209191-21-017903 · doc4.xml · derivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-02 F1 · derivative.exercise_date: This option was granted on March 2, 2021 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 3,443 | $6.14 | $21,145.18 |
DisclosureSEC source: 0001209191-21-006070 · doc4.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,172 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006070 · doc4.xml · derivative · entry 3 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-006070 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005640 · doc4.xml · derivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 23:26 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 4,041 | $2.42 | $9,775.58 |
DisclosureSEC source: 0001209191-20-043981 · doc4.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,115 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 23:26 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043981 · doc4.xml · derivative · entry 3 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 23:26 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043981 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037696 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,656 F1 · shares: The reported transaction is a grant of restricted stock units representing 75,000 shares of common stock. This grant will vest in two equal installments with the first fifty percent vesting on March 11, 2021 and the second fifty percent on March 11, 2022. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 20:53 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018918 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,656 F1 · shares: The reported transaction is a grant of restricted stock units representing 75,000 shares of common stock. This grant will vest evenly over 2 years with the first fifty percent vesting on the first anniversary of the grant date and the second fifty percent vesting on the second anniversary of the grant date. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:38 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Unit · Derivative | 23,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005412 · doc4.xml · derivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-01-27 F2 · derivative.exercise_date: The restricted stock units will vest in 2 installments. Fifty percent will vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date and will vest automatically as to 100% of the unvested portion of such restricted stock unit grant upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:38 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-20-005412 · doc4.xml · derivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2020 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 22:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0000899243-19-001954 · doc4.xml · derivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option was granted on January 23, 2019 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:11 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 8,542 | $31.10 | $265,624.59 |
DisclosureSEC source: 0000899243-18-029302 · doc4.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,656 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:11 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 13,448 | $30.68 | $412,555.05 |
DisclosureSEC source: 0000899243-18-029302 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,958 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| November 15, 2018 Filed Jan 10, 2019 21:45 UTC Amendment | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 8,542 | $31.10 | $265,624.59 |
DisclosureSEC source: 0000899243-19-000973 · doc4a.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,656 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. F4 · balance_after: Amendment corrects arithmetical error as to number of securities in Column 5 of Table I. Read SEC document |
| November 15, 2018 Filed Jan 10, 2019 21:45 UTC Amendment | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 13,448 | $30.68 | $412,555.05 |
DisclosureSEC source: 0000899243-19-000973 · doc4a.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,198 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. F4 · balance_after: Amendment corrects arithmetical error as to number of securities in Column 5 of Table I. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 105,677 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004335 · doc4.xml · derivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,677 Underlying: Common Stock · 105,677 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.